A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL V - Basal Insulin Switch)

Trial Profile

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL V - Basal Insulin Switch)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Insulin degludec/liraglutide (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DUAL V
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 09 Dec 2017 Results of an analysis comparing the results of the LixiLan and DUAL clinical development programmes, presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 08 Dec 2017 Results of a post-hoc analysis, presented at the 2017 Congress of the International Diabetes Federation.
    • 08 Dec 2017 Results of post hoc ananlysis from DUAL I and V assessing the effect of varying liraglutide doses within IDegLira presented at the 2017 Congress of the International Diabetes Federation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top